FDA approves oral dermatomyositis therapy
Phase 3 findings show improvements in physical function and skin disease activity.
-
By
-
Kathryn Wighton
-
August 28, 2026
-
Clinical Scorecard: FDA approves oral dermatomyositis therapy
At a Glance
| Category | Detail |
|---|
| Condition | Dermatomyositis |
| Key Mechanisms | Brepocitinib is a Janus kinase and tyrosine kinase 2 inhibitor that blocks immune and inflammatory pathways. |
| Target Population | Adults with dermatomyositis |
| Care Setting | Clinical treatment for autoimmune conditions |
Key Highlights
- First FDA-approved oral treatment for dermatomyositis.
- Brepocitinib showed improved Total Improvement Scores at week 52.
- Participants receiving brepocitinib had reduced corticosteroid use.
- Common adverse reactions included upper respiratory tract infection and headache.
- Brepocitinib carries a boxed warning for serious infections and other risks.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of dermatomyositis based on clinical criteria and muscle biopsy.
Management
- Brepocitinib is indicated for the treatment of adults with dermatomyositis.
Monitoring & Follow-up
- Monitor for adverse reactions and treatment efficacy at regular intervals.
Risks
- Serious infections, increased all-cause mortality, malignancies, major adverse cardiovascular events, and thrombosis.
Patient & Prescribing Data
Adults diagnosed with dermatomyositis.
Brepocitinib is administered once daily and may reduce the need for corticosteroids.
Clinical Best Practices
- Evaluate Total Improvement Score to assess treatment efficacy.
- Consider risk factors before prescribing brepocitinib.
Related Resources & Content
